Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agon

Structure Therapeutics (GPCR) announced upcoming presentations at the American Diabetes Association 85th Scientific Sessions, highlighting preclinical data for its oral small molecule ACCG-2671 as a potential obesity treatment and a separate GLP-1 receptor agonist showing neuroprotective effects in a Parkinson's disease model. ACCG-2671 demonstrated significant, dose-dependent weight loss in obese rats, with combination therapy showing superior results compared to monotherapy, while the GLP-1 receptor agonist improved motor coordination and increased dopaminergic neurons in preclinical models of Parkinson's.

Analysis

Structure Therapeutics (GPCR) is presenting positive preclinical data for two distinct oral small molecule candidates, reinforcing its pipeline strategy focused on metabolic and neurological diseases. The primary focus is on ACCG-2671 for obesity, a dual amylin and calcitonin receptor agonist. Preclinical results in diet-induced obese rats demonstrated significant, dose-dependent weight reductions. Critically, combination therapy with the GLP-1 receptor agonist semaglutide resulted in superior weight loss compared to monotherapy, positioning ACCG-2671 as a potential synergistic treatment alongside the current standard of care. The company anticipates initiating clinical development for this candidate by the end of 2025, providing a key upcoming milestone. Additionally, Structure is presenting data on a separate GLP-1 receptor agonist, GSBR-5595, which showed neuroprotective effects in a preclinical Parkinson’s disease model by improving motor function and preserving dopaminergic neurons. This second asset highlights the potential diversification of its platform beyond metabolic disorders, although both programs remain in the high-risk, early stages of development.

Key Decisions for Investors

• Consider the positive preclinical data for the obesity candidate ACCG-2671, particularly its synergistic effect with GLP-1 agonists, as a key value driver, but weigh it against the high risk associated with its early developmental stage.
• Monitor the company's execution on its stated timeline to initiate the ACCG-2671 Phase 1 study by the end of 2025, as this represents the next critical de-risking milestone for the asset.
• The positive data in a Parkinson's model offers potential long-term upside and pipeline diversification, but should be viewed as a secondary, higher-risk asset until it progresses into clinical development.